204 related articles for article (PubMed ID: 7496600)
1. Evaluation of proliferation parameters in in vivo bromodeoxyuridine labelled lung cancers.
Tinnemans MM; Lenders MH; ten Velde GP; Wagenaar SS; Blijham GH; Ramaekers FC; Schutte B
Virchows Arch; 1995; 427(3):295-301. PubMed ID: 7496600
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of proliferative cells.
Mokrý J; Nĕmecek S
Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1995; 38(3):107-13. PubMed ID: 8685626
[TBL] [Abstract][Full Text] [Related]
3. Comparison of labelling by bromodeoxyuridine, MIB-1, and proliferating cell nuclear antigen in gastric mucosal biopsy specimens.
Lynch DA; Clarke AM; Jackson P; Axon AT; Dixon MF; Quirke P
J Clin Pathol; 1994 Feb; 47(2):122-5. PubMed ID: 7907613
[TBL] [Abstract][Full Text] [Related]
4. A comparison of cellular proliferation markers in squamous cell carcinoma of the head and neck.
Jones AS; Roland NJ; Caslin AW; Cooke TG; Cooke LD; Forster G
J Laryngol Otol; 1994 Oct; 108(10):859-64. PubMed ID: 7989834
[TBL] [Abstract][Full Text] [Related]
5. DNA image cytometry and the expression of proliferative markers (proliferating cell nuclear antigen and Ki67) in non-Hodgkin's lymphomas.
Czader M; Porwit A; Tani E; Ost A; Mazur J; Auer G
Mod Pathol; 1995 Jan; 8(1):51-8. PubMed ID: 7731942
[TBL] [Abstract][Full Text] [Related]
6. Proliferating cell nuclear antigen and Ki-67 in lung carcinoma. Correlation with DNA flow cytometric analysis.
Kawai T; Suzuki M; Kono S; Shinomiya N; Rokutanda M; Takagi K; Ogata T; Tamai S
Cancer; 1994 Nov; 74(9):2468-75. PubMed ID: 7923002
[TBL] [Abstract][Full Text] [Related]
7. MIB-1, Ki67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas.
Pich A; Ponti R; Valente G; Chiusa L; Geuna M; Novero D; Palestro G
J Clin Pathol; 1994 Jan; 47(1):18-22. PubMed ID: 7907607
[TBL] [Abstract][Full Text] [Related]
8. Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression.
Cher ML; Chew K; Rosenau W; Carroll PR
Prostate; 1995 Feb; 26(2):87-93. PubMed ID: 7855002
[TBL] [Abstract][Full Text] [Related]
9. Validation of the use of proliferation markers in canine neoplastic and non-neoplastic tissues: comparison of KI-67 and proliferating cell nuclear antigen (PCNA) expression versus in vivo bromodeoxyuridine labelling by immunohistochemistry.
Zacchetti A; van Garderen E; Teske E; Nederbragt H; Dierendonck JH; Rutteman GR
APMIS; 2003 Mar; 111(3):430-8. PubMed ID: 12752223
[TBL] [Abstract][Full Text] [Related]
10. Comparison of proliferating cell nuclear antigen (PCNA) staining and BrdUrd-labelling index under different proliferative conditions in vitro by flow cytometry.
Lohr F; Wenz F; Haas S; Flentje M
Cell Prolif; 1995 Feb; 28(2):93-104. PubMed ID: 7893842
[TBL] [Abstract][Full Text] [Related]
11. Proliferating cell nuclear antigen (PCNA) immunostaining as an alternative to bromodeoxyuridine (BrdU) immunostaining for brain tumours in paraffin embedded sections.
Sasaki A; Naganuma H; Kimura R; Isoe S; Nakano S; Nukui H; Suzuki K; Kawaoi A
Acta Neurochir (Wien); 1992; 117(3-4):178-81. PubMed ID: 1357920
[TBL] [Abstract][Full Text] [Related]
12. Proliferating cell nuclear antigen expression in central nervous system neoplasms.
Allegranza A; Girlando S; Arrigoni GL; Veronese S; Mauri FA; Gambacorta M; Pollo B; Dalla Palma P; Barbareschi M
Virchows Arch A Pathol Anat Histopathol; 1991; 419(5):417-23. PubMed ID: 1721471
[TBL] [Abstract][Full Text] [Related]
13. Use of in situ detection of histone mRNA in the assessment of epidermal proliferation: comparison with the Ki67 antigen and BrdU incorporation.
Smith MD; Healy E; Thompson V; Morley A; Rees JL
Br J Dermatol; 1995 Mar; 132(3):359-66. PubMed ID: 7718451
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of five different methods for estimating proliferation in human colorectal adenocarcinomas.
Wilson MS; Anderson E; Bell JC; Pearson JM; Haboubi NY; James RD; Schofield PF
Surg Oncol; 1994 Oct; 3(5):263-73. PubMed ID: 7889219
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
[TBL] [Abstract][Full Text] [Related]
16. Growth fraction in non-small cell lung cancer estimated by proliferating cell nuclear antigen and comparison with Ki-67 labeling and DNA flow cytometry data.
Fontanini G; Pingitore R; Bigini D; Vignati S; Pepe S; Ruggiero A; Macchiarini P
Am J Pathol; 1992 Dec; 141(6):1285-90. PubMed ID: 1361306
[TBL] [Abstract][Full Text] [Related]
17. Comparison of brain tumor growth kinetics by proliferating cell nuclear antigen (PCNA) and bromodeoxyuridine (BrdU) labeling.
Lee KS; Yang WI
Yonsei Med J; 1992 Sep; 33(3):265-71. PubMed ID: 1363339
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of proliferating cell nuclear antigen, bromodeoxyuridine, and mitotic index in uveal melanoma.
Ghazvini S; Kroll S; Char DH; Frigillana H
Invest Ophthalmol Vis Sci; 1995 Dec; 36(13):2762-7. PubMed ID: 7499099
[TBL] [Abstract][Full Text] [Related]
19. Quantification of hepatocytic proliferation in the laboratory mouse. A comparative study using immunohistochemical detection of bromodeoxyuridine (BrdU) incorporation and proliferating cell nuclear antigen (PCNA) expression.
Lardelli P; Perentes E; Meier G; Navarro N; Ettlin RA
Exp Toxicol Pathol; 1994 Jul; 46(2):95-100. PubMed ID: 7987078
[TBL] [Abstract][Full Text] [Related]
20. Optimization of immunohistochemical staining of proliferating cells in paraffin sections of breast carcinoma using antibodies to proliferating cell nuclear antigen and the Ki-67 antigen.
Yu CC; Dublin EA; Camplejohn RS; Levison DA
Anal Cell Pathol; 1995 Jul; 9(1):45-52. PubMed ID: 7577754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
